Hilltop Holdings Inc. Buys 38,758 Shares of Pfizer Inc. $PFE

Hilltop Holdings Inc. grew its stake in Pfizer Inc. (NYSE:PFE) by 31.8% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 160,627 shares of the biopharmaceutical company’s stock after purchasing an additional 38,758 shares during the quarter. Hilltop Holdings Inc.’s holdings in Pfizer were worth $4,093,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of PFE. Fiduciary Alliance LLC boosted its position in Pfizer by 46.4% during the 3rd quarter. Fiduciary Alliance LLC now owns 145,263 shares of the biopharmaceutical company’s stock valued at $3,701,000 after acquiring an additional 46,043 shares in the last quarter. Y Intercept Hong Kong Ltd bought a new position in shares of Pfizer in the 3rd quarter worth approximately $3,019,000. Vista Investment Partners LLC lifted its stake in shares of Pfizer by 236.1% in the 3rd quarter. Vista Investment Partners LLC now owns 69,613 shares of the biopharmaceutical company’s stock valued at $1,774,000 after purchasing an additional 48,900 shares during the period. Money Concepts Capital Corp boosted its position in shares of Pfizer by 29.9% during the third quarter. Money Concepts Capital Corp now owns 248,251 shares of the biopharmaceutical company’s stock valued at $6,325,000 after purchasing an additional 57,188 shares in the last quarter. Finally, Kepler Cheuvreux Suisse SA purchased a new stake in Pfizer in the third quarter worth $16,613,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Down 1.0%

NYSE:PFE opened at $26.60 on Monday. The firm has a 50-day simple moving average of $26.50 and a two-hundred day simple moving average of $25.53. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $27.94. The firm has a market cap of $151.23 billion, a P/E ratio of 19.56 and a beta of 0.47.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The firm had revenue of $17.56 billion for the quarter, compared to the consensus estimate of $16.93 billion. During the same period in the prior year, the company posted $0.63 earnings per share. The company’s quarterly revenue was down 1.2% on a year-over-year basis. Analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: China approves Pfizer’s GLP‑1 weight‑management drug Xianweiying, opening a large, fast‑growing market and adding a new commercial revenue stream in 2026+ — potential upside to international sales. Pfizer’s Weight Management Drug Wins China Approval
• Positive Sentiment: Promising Phase 2 results for tilrekimig (trispecific antibody) in atopic dermatitis reinforce Pfizer’s immunology pipeline; if confirmed in later trials, this could be a material franchise expansion. How Tilrekimig’s Trispecific Eczema Data At Pfizer (PFE) Has Changed Its Investment Story
• Positive Sentiment: Pfizer advanced an early‑stage oncology candidate (PF‑07994525), expanding its cancer pipeline and showing continued R&D momentum in higher‑value therapeutic areas. Pfizer Advances Early-Stage Cancer Candidate PF-07994525
• Positive Sentiment: Scotiabank reaffirmed a Buy rating on PFE, providing analyst support that can help stabilize sentiment among institutional holders. Scotiabank Sticks to Their Buy Rating for Pfizer (PFE)
• Neutral Sentiment: Market research reports highlight long‑acting growth‑hormone (Ngenla/somatrogon) market expansion and regional opportunities (Asia‑Pacific growth), useful for medium‑term planning but not immediate earnings. Ngenla (somatrogon: Pfizer) Market Research Report 2026
• Neutral Sentiment: Separate market research on Tivdak (tisotumab vedotin) underscores oncology demand and biomarker opportunities; supportive for long‑term growth but not an immediate catalyst. Tivdak (Genmab, Pfizer: tisotumab vedotin-tftv) Market Research Report 2026
• Neutral Sentiment: Industry reports on AI in life sciences list Pfizer among firms accelerating AI‑driven drug discovery; this supports long‑run efficiency gains but faces regulatory/cost adoption timelines. AI in Life Sciences Market, 2026-2040
• Negative Sentiment: Persistent headwinds — post‑COVID revenue normalization and drug‑pricing pressure — continue to weigh on sentiment; commentary urging buy due to a high dividend yield reflects a lower share‑price base rather than improving top‑line momentum. 1 Magnificent Dividend Stock Down 57% to Buy and Hold Forever
• Negative Sentiment: Short‑term sell pressure: outlets and data summaries note PFE has dipped more than the broader market in recent sessions, suggesting positioning/rotation risk for today’s weakness. Pfizer (PFE) Sees a More Significant Dip Than Broader Market

Wall Street Analyst Weigh In

PFE has been the subject of a number of research reports. HSBC reiterated a “buy” rating and issued a $29.00 price objective on shares of Pfizer in a report on Wednesday, December 10th. Daiwa Securities Group lowered shares of Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price target for the company. in a research note on Thursday, February 12th. Royal Bank Of Canada assumed coverage on shares of Pfizer in a research report on Tuesday, February 24th. They set an “underperform” rating and a $25.00 price target for the company. Guggenheim reissued a “buy” rating on shares of Pfizer in a research note on Wednesday, December 17th. Finally, Bank of America cut their price objective on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a report on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, fourteen have issued a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $28.05.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.